You are here: Industry Insights > Cimzia

News List

UCB’s Cimzia bags EU label extension pharmatimes
August 07, 2020
The European Medicines Agency (EMA) has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adult patients with axial spondyloarthritis (axSpA) at a reduced maintenance dose.
NICE recommends UCB's Cimzia in severe plaque psoriasis pharmafiles
April 23, 2019
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in the treatment of severe plaque psoriasis in patients who have failed to respond to, or are unsuitable for, other systemic treatments.
NICE final guidance published for Cimzia pharmatimes
April 21, 2019
The National Institute for Health and Care Excellence (NICE) has shared its final guidance for the recommended use of UCB’s Cimzia (certolizumab pegol).
Health Canada Approves CIMZIA (certolizumab pegol) for Moderate-to-Severe Psoriasis firstwordpharma
March 26, 2019
UCB Canada Inc. announced today that Health Canada has approved a new indication for……
Cimzia maker UCB takes next step in pregnancy initiative for women with IBD with 'Parenthood Project' campaign fiercepharma
February 24, 2019
Thanks to worries and misconceptions about their health, women with inflammatory bowel disease are up to three times more likely than other women to choose not to have children.
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis pharmaphorum
December 06, 2018
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money.
EMA approves Cimzia for use in treating plaque psoriasis pharmafile
July 06, 2018
The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis.